| Migraine Disorders
Nurtec ODT vs Vyepti
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Nurtec Odt vs Vyepti with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyepti has a higher rate of injection site reactions vs Nurtec Odt based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyepti but not Nurtec Odt, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nurtec Odt
Vyepti
At A Glance
Oral
As needed or every other day
CGRP receptor antagonist
IV infusion
Every 3 months
CGRP antagonist
Indications
- Migraine Disorders
- Episodic migraine
- Migraine Disorders
Dosing
Migraine Disorders 75 mg orally as needed; maximum 75 mg per 24-hour period; safety of more than 18 doses in a 30-day period has not been established; may be taken with or without food.
Episodic migraine 75 mg orally every other day, with or without food.
Migraine Disorders 100 mg by IV infusion every 3 months; some patients may benefit from 300 mg by IV infusion every 3 months.
Contraindications
- History of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components, including anaphylaxis and delayed serious hypersensitivity
- Serious hypersensitivity to eptinezumab-jjmr or any excipient, including anaphylaxis and angioedema
Adverse Reactions
Most common Nausea, abdominal pain/dyspepsia
Serious Hypersensitivity including dyspnea and severe rash
Postmarketing Hypersensitivity (anaphylaxis), hypertension, Raynaud's phenomenon
Most common (>=2%) nasopharyngitis, hypersensitivity reactions
Postmarketing anaphylaxis, fatigue, hypertension, Raynaud's phenomenon
Pharmacology
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it is an orally administered small molecule that blocks the CGRP receptor implicated in migraine pathophysiology, indicated for both acute and preventive treatment.
Eptinezumab-jjmr is a humanized IgG1 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, thereby preventing CGRP-mediated effects relevant to migraine.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nurtec Odt
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (12/12)
Vyepti
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Nurtec Odt
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Vyepti
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Nurtec Odt
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Vyepti
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Nurtec OdtView full Nurtec Odt profile
VyeptiView full Vyepti profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.